

Ophthotech Corp

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 18-Feb-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 9

 Phase 3 Clinical..... 10

 Phase 2 Clinical..... 13

[Return to Table of Contents](#)

Ophthotech Corp

COMPANY OVERVIEW

Company Name	Ophthotech Corp
Parent Company Name	Ophthotech Corp
Website	http://www.ophthotech.com/
Country	US
Number of Drugs in Active Development	2
Number of Inactive Drugs	2
Number of Patents as Owner	6
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Age related macular degeneration, Dry age related macular degeneration, Wet age related macular degeneration, Diabetic retinopathy, Choroidal neovascularization, Ocular disease, Macular degeneration, Retinopathy, Angiomas, Aortic aneurysm, Arterial occlusive disease, Neoplasm, Vascular disease, Venous occlusive disease
Key Target-based Actions	VEGF receptor antagonist, Integrin alpha-5/beta-1 antagonist, PDGF receptor antagonist, BTG2 gene inhibitor, VEGF ligand inhibitor
Key Technologies	Drug combination, Ophthalmic formulation, Protein fusion, Antibody fragment, Cell delivery system, Chimeric monoclonal antibody, Directed prodrug therapy, Formulation preservation, Intravenous formulation, Monoclonal antibody, Peptide, Peptidomimetic, Polynucleotide sequence

COMPANY PROFILE

SUMMARY

Ophthotech Corp develops therapies for back-of-the-eye diseases.

FINANCIAL

In February 2014, Ophthotech commenced an underwritten public offering of 1.9 million common stock shares. At that time, the company expected to grant the underwriters an option for a period of 30 days to buy up to an additional 285,000 shares of common stock at the public offering price, less the underwriting discount. The company would not receive any proceeds from the sale of shares by the stockholders; later that month, the underwritten public offering of 2,285,714 shares were priced at \$31.50 per share and the underwriters were granted up to an additional 342,857 shares. In the offering, 1,900,000 and 385,714 shares were being sold by the company and certain stockholders of the company, respectively. At that time, the offering was expected to close on or about February 18, 2014.

In September 2013, Ophthotech announced the public offering of 7,600,000 shares of common stock priced at \$22.00 each. The underwriters were given a period of 30 days to purchase up to 1,140,000 additional shares of common stock at the public offering price, less the underwriting discount. Ophthotech's common stock has been approved for listing on the NASDAQ under the ticker symbol 'OPHT'. Later in September 2013, Ophthotech closed the IPO of 8,740,000 common stock shares, including full exercise of the underwriters' option. In November 2013, the company reported that it had raised \$192 million in the IPO and began trading from September 25, 2013.

In August 2013, Ophthotech filed a registration statement on Form S-1 with the US SEC for a proposed initial public offering of its common stock.

In May 2013, Ophthotech closed the first of three equal tranches of a \$175 million financing, which comprised \$125 million royalty funding and \$50 million Series C preferred stock financing from Novo A/S. In January 2014, the company received \$41.7 million in a second tranche.

In December 2009, Ophthotech raised \$30 million from a series B financing.

In August 2007, Ophthotech raised \$36 million from a series A financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	2	2	4

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
No Development Reported	2

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	4	0	4

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	3	8

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 3	3	3
Phase 2	0	1
Phase 1	0	4

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	0	5
Genitourinary disease	1	0	1
Immune disorder	1	0	1
Neoplasm	2	0	2
Ocular disease	5	0	5
Neurological disease	1	0	1
Respiratory disease	1	0	1
Infectious disease	1	0	1
Inflammatory disease	1	0	1
Dermatological disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

Fovista

Fovista SNAPSHOT

Drug Name	Fovista
Key Synonyms	Fovista
Originator Company	Archemix Corp
Active Companies	Ophthotech Corp
Inactive Companies	Eyetech Inc;Archemix Corp
Highest Status	Phase 3 Clinical
Active Indications	Wet age related macular degeneration
Target-based Actions	PDGF receptor antagonist;PDGF-B ligand inhibitor
Other Actions	Ophthalmological agent
Technologies	Oligonucleotide;PEGylated formulation;Ophthalmic formulation;Biological therapeutic;Small molecule therapeutic
Last Change Date	03-Feb-2014

Fovista DEVELOPMENT PROFILE

SUMMARY

Ophthotech, under license from (OSI) Eyetech and Archemix, is developing Fovista (formerly known as E-10030), a PEGylated aptamer directed against PDGF-B administered via intravitreal injection, for the potential treatment of neovascular age-related macular degeneration (AMD) or wet AMD, both as a single agent and in combination with pegaptanib . In August 2013, a phase III trial was initiated in patients with wet AMD ; later that month another phase III trial was initiated . In January 2014, an IND was expected to be filed in 2016; at that time, the company planned to seek partners for commercialization outside the US.

Archemix and Eyetech were also investigating E-10030, but this collaboration was presumed to have been discontinued when Ophthotech acquired all rights to the drug from (OSI) Eyetech.

Fovista DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ophthotech Corp	Wet age related macular degeneration	Australia	Phase 3 Clinical	31-Aug-2013
Ophthotech Corp	Wet age related macular degeneration	Canada	Phase 3 Clinical	31-Aug-2013
Ophthotech Corp	Wet age related macular degeneration	US	Phase 3 Clinical	29-Aug-2013

[Return to Table of Contents](#)

Company	Indication	Country	Development Status	Date
Ophthotech Corp	Wet age related macular degeneration	Europe	Phase 2 Clinical	26-Apr-2010
Ophthotech Corp	Wet age related macular degeneration	South America	Phase 2 Clinical	26-Apr-2010
Archemix Corp	Age related macular degeneration	US	Discontinued	27-Jul-2007
Eyetech Inc	Age related macular degeneration	US	Discontinued	27-Jul-2007

Fovista DRUG NAMES

Names	Type
platelet-derived growth factor B antagonist, (macular degeneration), Eyetech/Archemix	
platelet-derived growth factor B antagonist, (macular degeneration), (OSI) Eyetech/Archemix	
E-10030	Research Code
Fovista	Trade Name
PDGF-B antagonist (wet AMD), Ophthotech	
PDGF-B antagonist (AMD), Eyetech/Archemix	
PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix	

Fovista CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Age related macular degeneration											
0	0	2	2	0	0	0	1	0	0	2	3
Choroidal neovascularization											
0	0	2	2	0	0	0	0	0	0	2	2
Wet age related macular degeneration											
0	0	1	1	0	1	0	0	0	0	1	2

[Return to Table of Contents](#)

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	3	3	0	1	0	1	0	0	3	5

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)



Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

Fovista DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Archemix Corp	1	1	0	0	2
Valeant Pharmaceuticals International Inc	1	0	0	1	2
Ophthotech Corp	0	0	2	0	2

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	1	3

[Return to Table of Contents](#)

ARC-1905

ARC-1905 SNAPSHOT

Drug Name	ARC-1905
Key Synonyms	Zimura
Originator Company	Archemix Corp
Active Companies	Ophthotech Corp
Inactive Companies	Archemix Corp
Highest Status	Phase 2 Clinical
Active Indications	Age related macular degeneration;Dry age related macular degeneration
Target-based Actions	Complement C5a receptor antagonist
Other Actions	Complement cascade inhibitor
Technologies	PEGylated formulation;Ophthalmic formulation;Small molecule therapeutic
Last Change Date	14-Jan-2014

ARC-1905 DEVELOPMENT PROFILE

SUMMARY

Ophthotech, under license from Archemix, is developing ARC-1905 (Zimura), a PEGylated anti-C5 aptamer, for the potential treatment of wet and dry age-related macular degeneration (AMD). In October 2008, a phase I trial began ; in May 2009, initial results from the trial were reported. In March 2009, Ophthotech was planning to initiate a second phase I trial in dry AMD subjects. By January 2014, a phase IIa study for dry AMD was complete and a phase II study for wet AMD was planned

Ophthotech is also investigating ARC-186, an unPEGylated anti-C5 aptamer.

ARC-1905 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Ophthotech Corp	Dry age related macular degeneration	US	Phase 2 Clinical	13-Jan-2014
Ophthotech Corp	Age related macular degeneration	US	Phase 1 Clinical	27-Oct-2008
Archemix Corp	Age related macular degeneration	US	Discontinued	13-Aug-2007

[Return to Table of Contents](#)

ARC-1905 DRUG NAMES

Names	Type
ARC-1905	Research Code
aptamer C5 inhibitors (age-related macular degeneration), Archemix/Ophthotech	
Zimura	Trade Name

ARC-1905 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Age related macular degeneration											
0	0	0	0	0	0	0	2	0	0	0	2

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	2	0	0	0	2

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical



Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

ARC-1905 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Active Deals
Total: 1

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Archemix Corp	1	0	0	0	1
Ophthotech Corp	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

